BROWSE·page 111 of 320

Browse EX-10 agreements

3,838 matching material contract exhibits.


EXCLUSIVITY LETTER

Edgemode, Inc.

EdgeMode Inc

Nevada U.S.A - Tax ID 47-4046237

110, East Broward Blvd, Fort Lauderdale, Florida, 33301

DATE:   01-Jul-26

Dear Sirs,

Re: Data centre development land in Spain

This exclusivity letter (“Exclusivity Letter”) sets forth our understanding and agreement regarding the exclusive negotiations between Pure Data Centres Group Limited (“Pure DC”) and EdgeMode Inc (“Edgemode”).

On or around the date of this Exclusivity Letter, Pure DC and Edgemode have entered into a term sheet (the “Term Sheet”) in relation to land in Spain for the development and leasing of hyperscale data centres, (“Proposed Transaction”), as further detailed in the Term Sheet, a copy of which is annexed to this Exclusivity Letter.

Exclusivity: From the date of acceptance of this Exclusivity Letter, Pure DC shall be granted exclusivity for a period of sixty (60) days (the “Exclusivity Period”) in relation to the Proposed Transaction and the sites, controlled by Edgemode, known as Cordoba, Palma, Vianos and Caceres.

EX-10.2·8-K·CIK 1652958·ACC 0001683168-26-005308·Filed Jul 06, 2026, 16:05 ET

TERM SHEET

Edgemode, Inc.

SUBJECT TO CONTRACT

| |

EX-10.1·8-K·CIK 1652958·ACC 0001683168-26-005308·Filed Jul 06, 2026, 16:05 ET

EXHIBIT 10.1

IGC Pharma, Inc.

** **

STOCK PURCHASE AGREEMENT

This Stock Purchase Agreement (this “Agreement”) is entered into as of June 30, 2026, by and between IGC Pharma, Inc., a Maryland corporation (the “Company”), and the Purchaser (“Purchaser”).

1. Purchase and Sale of Shares

Subject to the terms and conditions of this Agreement, the Company hereby agrees to issue and sell to the Purchaser, and the Purchaser hereby agrees to purchase from the Company, _________ shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a purchase price of $0.27 per Share.

2. Consideration; Cancellation of Indebtedness

The aggregate purchase price for the Shares is __________. The purchase price shall be paid by the Purchaser through the cancellation and satisfaction of ___________outstanding owed by the Company to the Purchaser as of the date hereof.

EX-10.1·8-K·CIK 1326205·ACC 0001185185-26-002808·Filed Jul 06, 2026, 16:02 ET

EX-10.1

COMMERCE BANCSHARES INC /MO/

Notice of Grant of Award

and Award Agreement

(this “Agreement”)

Commerce Bancshares, Inc.

ID: 43-0889454

1000 Walnut St.

Kansas City, MO 64106

THIS DOCUMENT CONSTITUTES PART OF A PROSPECTUS COVERING SECURITIES THAT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933

[ Participant Name ]

[ Employee ID ]

[ Participant ID ]

Award Number: [ ###### ]

Effective [ Grant Date ] (the "Grant Date"), you (“Grantee”) have been granted [ Number of Units Granted ] Restricted Stock Units pursuant to the Commerce Bancshares, Inc. (the “Company”) Equity Incentive Plan, as amended and restated effective April 19, 2023 (the “Plan”). Each Restricted Stock Unit represents the right to receive one Share of Common Stock upon the conclusion of the period beginning on the Grant Date and ending on the Vesting Date (as defined below) (the “Period of Restriction”). The terms and conditions of your grant (the “Award”) are discussed below.

EX-10.1·8-K·CIK 22356·ACC 0000022356-26-000169·Filed Jul 06, 2026, 16:01 ET

** **

TRUST AMENDMENT


Juen 30, 2026

THIS AMENDMENT TO THE INVESTMENT MANAGEMENT TRUST AGREEMENT (this “Amendment”) is made as of June 30, 2026, by and between Eureka Acquisition Corp, a Cayman Islands company (the “Company”), and Continental Stock Transfer & Trust Company (the “Trustee”). Capitalized terms contained in this Amendment, but not specifically defined in this Amendment, shall have the meanings ascribed to such terms in that certain Investment Management Trust Agreement, dated July 2, 2024, as amended on June 30, 2025, by and between the parties hereto (the “Trust Agreement”).

WHEREAS, the Company and the Trustee entered into an Investment Management Trust Agreement dated as of July 2, 2024;

WHEREAS, each of the Company and Trustee desire to amend the Trust Agreement as provided herein.

NOW, THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows:

EX-10.1·8-K·CIK 2000410·ACC 0001213900-26-075470·Filed Jul 06, 2026, 16:00 ET

FIRST AMENDMENT TO SENIOR SECURED PROMISSORY NOTE

(December 2024 Senior Secured Note)

This First Amendment (“Amendment”) is entered into as of June 30, 2026, by and between Bespoke Extracts, Inc., a Nevada corporation (the “Company”), and the undersigned holder (the “Holder”) of the Company’s Senior Secured Promissory Note originally issued in December 2024 (the “Note”).

WHEREAS, the Note bears interest at 15% per annum and matures June 30, 2026; and the Company and Holder wish to extend the maturity date, increase the interest rate for the extension period, and grant the Holder additional shares in consideration, pursuant to Section 8 of the Note, which permits amendment with Simple Majority consent binding on all holders of the series;

NOW, THEREFORE, the parties agree as follows:

1. Extended Maturity Date

EX-10.1·8-K·CIK 1409197·ACC 0001213900-26-075364·Filed Jul 06, 2026, 13:43 ET

EXHIBIT 10.2

Liminatus Pharma, Inc.

NON-COMPETITION AND NON-SOLICITATION AGREEMENT

This Non-Competition and Non-Solicitation Agreement (this “Agreement”) is entered into as of June 29, 2026, by and between InnocsAI LLC, a Delaware limited liability company (together with its successors, the “Company”), and the undersigned party listed under Subject Party on the signature page hereto (the “Subject Party”) in favor of and for the benefit of Liminatus Pharma, Inc., a Delaware corporation (“Purchaser”), and each of Purchaser’s Affiliates, successors and direct and indirect Subsidiaries, including the Company Group (together with the Company and Purchaser, the “Covered Parties”). Any capitalized term used but not defined in this Agreement shall have the meaning ascribed to such term in the Merger Agreement (as defined below).

EX-10.2·8-K·CIK 1971387·ACC 0001104659-26-080613·Filed Jul 06, 2026, 09:13 ET

EXHIBIT 10.1

Liminatus Pharma, Inc.

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of June 29, 2026, by and among Liminatus Pharma, Inc., a Delaware corporation (the “Company”) and the undersigned parties listed under Stockholders on the signature page hereto (each, an “Stockholder” and collectively, the “Stockholders”).

WHEREAS, pursuant to a Merger Agreement, dated as of May 17, 2026 and amended and restated as of June 29, 2026 (as further amended and supplemented from time to time, the “Merger Agreement”), by and among the Company, InnocsAI LLC, Delaware limited liability company (“InnocsAI”), NamChul Jung, an individual, as the representative of the members of InnocsAI, the Stockholders agreed to accept the Merger Shares (i.e., Common Stock and Preferred Stock of the Company) in exchange for their membership interests of InnocsAI;

EX-10.1·8-K·CIK 1971387·ACC 0001104659-26-080613·Filed Jul 06, 2026, 09:13 ET

EX-10.1

TUTOR PERINI CORP

Execution Version 1760749406.12 AMENDED AND RESTATED CREDIT AGREEMENT Dated as of July 2, 2026 among TUTOR PERINI CORPORATION, as the Borrower, THE SUBSIDIARIES OF THE BORROWER IDENTIFIED HEREIN, as the Guarantors, BMO BANK N.A., as Administrative Agent and THE OTHER LENDERS PARTY HERETO BMO CAPITAL MARKETS CORP., GOLDMAN SACHS BANK USA, DEUTSCHE BANK AG NEW YORK BRANCH and MANUFACTURERS AND TRADERS TRUST COMPANY as Joint Lead Arrangers and Joint Bookrunners


EX-10.1·8-K·CIK 77543·ACC 0000077543-26-000163·Filed Jul 06, 2026, 09:03 ET

EXHIBIT 10.1

Capstone Holding Corp.

FIRST AMENDMENT TO AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT

This FIRST AMENDMENT TO AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT (this “Amendment”), is entered into as of July 2, 2026, by and between Capstone Holding Corp., a Delaware corporation (the “Company”), and Tumim Stone Capital, LLC, a Delaware limited liability company (the “Investor”).

WHEREAS:

A.        The Company and Investor executed and delivered that certain Amended and Restated Common Stock Purchase Agreement, dated as of June 16, 2026 (the “Purchase Agreement”); and

B.          The Company and Investor wish to amend the Purchase Agreement in certain respects.

NOW THEREFORE, the Company and the Investor severally (and not jointly) hereby agree as follows:

1.          CAPITALIZED TERMS. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement.

2.            AMENDMENT.

EX-10.1·8-K·CIK 887151·ACC 0001437749-26-022686·Filed Jul 06, 2026, 09:00 ET

** **

AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT

** **

***
***THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT (this “Amendment”) is dated as of July 6, 2026, by and between iPower Inc., a Nevada corporation (the “Company”) and the undersigned (the “Investor”), and amends that certain Securities Purchase Agreement, dated as of December 22, 2025, by and among the Company and each of the investors listed on the Schedule of Buyers attached thereto (the “Securities Purchase Agreement”). Capitalized terms used herein but not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement.

WHEREAS, the Company and the Investor desire to amend certain provisions of the Securities Purchase Agreement pursuant to Section 9(e) thereof.

WHEREAS, pursuant to Section 9(e) of the Securities Purchase Agreement, the Company and the Investor, in its capacity as the Required Holder, may amend the terms of the Securities Purchase Agreement.

EX-10.2·8-K·CIK 1830072·ACC 0001683168-26-005288·Filed Jul 06, 2026, 08:45 ET

** **

EXECUTION VERSION

**NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE, INCLUDING SECTIONS 3(c)(iii) AND 20(a) HEREOF. THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDING

EX-10.1·8-K·CIK 1830072·ACC 0001683168-26-005288·Filed Jul 06, 2026, 08:45 ET